AUAUniversity

AUA2024: Ramon Guiteras Lecture: Modern Innovation: Promise or Peril?

Presenter: Craig Niederberger, MD, FACS

AUA Leadership and Business Podcast: Urology Practice Manage - Overcoming Operational Challenges

This episode is brought to you by the AUA Leadership and Business Podcast, where urologic professionals experience the practical application of business acumen essential to successfully navigating today’s rapidly changing business environment! Subscribe today via your favorite podcast app.

Focal Therapy Options for Prostate Cancer

AUA Urology Core Curriculum: auau.auanet.org/core

Host: Jay D. Raman, MD, FACS, FRCS(Glasg)

Guest: Ruben Olivares, MD

Outline:

Segment 1: Why Focal Therapy?

Segment 2: Patient selection for Focal Therapy

Segment 3: Review of Existing Focal Therapy Modalities

Segment 4: How to Build a Successful Focal Therapy Program

Hereditary Kidney Cancer Syndromes

CME Available: https://auau.auanet.org/node/41772

ACKNOWLEDGEMENTS:

Support provided by an independent educational grant from: 

Merck & Co., Inc. 

LEARNING OBJECTIVES:

At the conclusion of this activity, participants should be able to:

1. Select patients who should undergo genetic testing to identify hereditary kidney cancer syndromes based on appropriate criteria, including family history and clinical presentation.

2. Implement strategies to address ethical concerns related to genetic testing, such as patient consent, confidentiality, and the potential impact on family members.

3. Discuss VHL syndrome, including its genetic basis, inheritance pattern, and associated tumors.

4. Properly diagnose and manage VHL syndrome in clinical practice based on knowledge of novel therapeutic strategies.

5. Utilize a multidisciplinary approach consisting of urologists, oncologists, geneticists and nephrologists when managing hereditary kidney cancer syndromes.

Prostate Cancer Update (2024): Expert Guidance for Urologists

CME Available: https://auau.auanet.org/node/41868

Acknowledgements

Support provided by independent educational grants from:

Astellas

Lantheus Medical Imaging

Novartis Pharmaceuticals Corporation

Pfizer, Inc.

Learning Objectives

At the conclusion of this activity, the learner will:

1. Align their practice with current AUA Guidelines (and recent amendments) pertaining to Screening, Diagnosis, and Management of Prostate Cancer.

2. Determine appropriate use of biomarker testing as it relates to diagnosis and therapy.

3. Analyze the role of imaging and types of imaging that aid in staging patients with prostate cancer.

4. Implement appropriate treatment paradigms for metastatic prostate cancer including treatment intensification.

5. Discuss the role of genetic and molecular profiling in the personalization of prostate cancer treatment plans.

Treatment Intensification in Metastatic HSPC

CME Available: https://auau.auanet.org/node/41733

ACKNOWLEDGEMENTS:

Support provided by independent educational grants from: 

Lantheus Medical Imaging

Novartis Pharmaceuticals Corporation

LEARNING OBJECTIVES:

At the conclusion of this activity, participants will be able to:

1. Explain the rationale behind treatment intensification in metastatic hormone sensitive prostate cancer (mHSPC), based on its pathophysiology. 

2. Analyze the rationale and clinical evidence supporting treatment intensification in mHSPC, including potential benefits and risks. 

3. Select appropriate patients for treatment intensification, considering factors such as disease burden, patient comorbidities, and individual risk profiles.

Appropriate Use of Genetic Testing (who, what, when and how?)

CME Available: https://auau.auanet.org/node/41734

ACKNOWLEDGEMENTS:

Support provided by independent educational grants from: 

Lantheus Medical Imaging

Novartis Pharmaceuticals Corporation

LEARNING OBJECTIVES:

At the conclusion of this activity, participants will be able to:

1. Identify the patient populations that should be considered for genetic testing in prostate cancer, based on family history, personal risk factors, and clinical indications.

2. Integrate genetic testing into clinical practice for prostate cancer, including developing workflows, referral processes, and multidisciplinary collaboration.

3. Utilize genetic test results to inform personalized treatment plans for prostate cancer patients, including targeted therapies and risk reducing strategies.

Sequencing Of Agents

ACKNOWLEDGEMENTS:

Support provided by independent educational grants from:

Lantheus Medical Imaging

Novartis Pharmaceuticals Corporation

LEARNING OBJECTIVES:

At the conclusion of this activity, participants will be able to:

1. Review the latest evidence and clinical guidelines that inform the sequencing of therapeutic agents in metastatic prostate cancer, including data from key clinical trials.

3. Implement strategies for managing and overcoming resistance to therapy in metastatic prostate cancer, considering the role of sequencing in delaying resistance.

4. Apply best practices for monitoring treatment response and disease progression in patients undergoing therapy, and adjust sequencing strategies based on these observations.

Urologic Oncology: Genetics And Genomics

AUA Urology Core Curriculum: auau.auanet.org/core

Host: Jay D. Raman, MD, FACS, FRCS(Glasg)

Guest: Hong Truong, MD, MS

Outline:

Segment 1: Genetics 101 – How Genes Influence Cancer Risk

Segment 2: Genetic Risk Assessment

Segment 3: Genetics of Kidney Cancer

Segment 4: Genetics of Upper Tract Cancer

Segment 5: Genetics of Prostate Cancer

Biomarkers and Molecular Imaging for Prostate Cancer

CME Available: https://auau.auanet.org/node/41727

ACKNOWLEDGEMENTS:

Support provided by independent educational grants from: 

Lantheus Medical Imaging

Novartis Pharmaceuticals Corporation

LEARNING OBJECTIVES:

At the conclusion of this activity, participants will be able to:

1. Explain the principles of molecular imaging and its application in prostate cancer, including techniques such as PET, MRI, and novel radiotracers.

2. Evaluate recent advances in molecular imaging technologies and their role in improving the accuracy of prostate cancer diagnosis, staging, and treatment monitoring.

3. Define and classify different types of biomarkers relevant to prostate cancer, including diagnostic, prognostic, and predictive biomarkers.